Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-HPArk2 SPECT/CT for Detection of HER2-positive Breast Cancer
NCT04267900Phase 1Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 99mTc-HP-Ark2 in breast cancer, sponsored by Peking Union Medical College Hospital. Primary endpoint: Standardized uptake value at 1 year. Started Dec 2019; status: completed.
02
Drugs
99mTc-HP-Ark2
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04267900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267900.